Disclosures: Luz Esther Ramos Ballesteros: Nothing to Disclose, Bertrand Lebouch: Merck Canada: Speaking and Teaching, Gilead: Speaking and Teaching, ViiV healthcare: Consultant, Gilead: ASAP study managed by RI-MUHC, Merck: I score study and core set study managed by RI-MUHC, ViiV: PIVHOT progra mfro patients managed by RI-MUHC, Jean-Pierre Routy: Nothing to Disclose, Marina Klein: Nothing to Disclose, Jason Szabo: Nothing to Disclose, Joseph Cox: Nothing to Disclose, Julian Falutz: EMD Sermon: Advisor, ViiV: Speaking and Teaching, Merck: Speaking and Teaching, Louis-Patrick Haraoui: Nothing to Disclose, Cecilia Costiniuk: Nothing to Disclose, Alexandra De Pokomandy: Nothing to Disclose, Felice Cinque: Nothing to Disclose, Tom Pembroke: Nothing to Disclose, Marco Constante: Nothing to Disclose, Manuela Santos: Nothing to Disclose, Giada Sebastiani: Novo Nordisk: Consultant, Abbvie: Speaking and Teaching, Merck: Consultant, Gilead: Speaking and Teaching, Theratechnologies Inc.: Grant/Research Support 1178 NEW STEATOTIC LIVER DISEASE DIAGNOSTIC PERFORMANCE IN A CHILEAN AGRICULTURAL POPULATION COHORT Maria Spencer Sandino 1 Laura Andrea Huidobro 2 Franco Godoy 1 Danilo Alvares 3 Juan Pablo Arab 4 Daniel Cabrera 5 Marco Arrese 1 Francisco Barrera 1 Catterina Ferreccio 1 , 1 Pontificia Universidad Catlica de Chile, 2 Universidad Catlica del Maule, 3 University of Cambridge, 4 Western University and London Health Sciences Centre, 5 Universidad de los Andes Background: Non- alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease globally, with rising rates, particularly in Latin America, due to the increasing tide of obesity and type 2 diabetes
hence, targeting tryptophan metabolism with combinatorial approaches may yield optimal therapies [123]
It comes in daily tablets (for alcohol use disorder) and as a monthly intramuscular injection (for opioid use disorder or alcohol use disorder).(20) All medical professionals and relevant agencies of the United States federal government, such as the National Institutes for Drug Abuse, agree that treatment of opioid use disorder with MOUD is not the substitute of one addiction for another
CONCLUSION: In spite of widespread reported use, there are no studies of IV GSH use for skin lightening or of its safety for chronic use (for any indication)
